Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D'Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, Sinno V, Ronzulli D, Giolitto S, de Braud F. Lorusso D, et al. Among authors: raspagliesi f. Target Oncol. 2021 Jan;16(1):59-68. doi: 10.1007/s11523-020-00780-4. Epub 2020 Dec 28. Target Oncol. 2021. PMID: 33369704 Free PMC article. Clinical Trial.
The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.
Di Leo A, Bajetta E, Nolè F, Biganzoli L, Ferrari L, Oriana S, Riboldi G, Bohm S, Spatti G, Raspagliesi F, et al. Di Leo A, et al. Among authors: raspagliesi f. Br J Cancer. 1994 May;69(5):961-6. doi: 10.1038/bjc.1994.186. Br J Cancer. 1994. PMID: 7514030 Free PMC article. Clinical Trial.
Management of peritoneal surface component of ovarian cancer.
Deraco M, Raspagliesi F, Kusamura S. Deraco M, et al. Among authors: raspagliesi f. Surg Oncol Clin N Am. 2003 Jul;12(3):561-83. doi: 10.1016/s1055-3207(03)00027-9. Surg Oncol Clin N Am. 2003. PMID: 14567018 Review.
Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.
Bolis G, Scarfone G, Polverino G, Raspagliesi F, Tateo S, Richiardi G, Melpignano M, Franchi M, Mangili G, Presti M, Villa A, Conta E, Guarnerio P, Cipriani S, Parazzini F. Bolis G, et al. Among authors: raspagliesi f. J Clin Oncol. 2004 Feb 15;22(4):686-90. doi: 10.1200/JCO.2004.03.017. J Clin Oncol. 2004. PMID: 14966092 Free article. Clinical Trial.
Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.
Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, Younan R, Baratti D, Mariani L, Laterza B, Deraco M. Raspagliesi F, et al. Eur J Surg Oncol. 2006 Aug;32(6):671-5. doi: 10.1016/j.ejso.2006.03.011. Epub 2006 Apr 18. Eur J Surg Oncol. 2006. PMID: 16621425
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.
Bolis G, Scarfone G, Raspagliesi F, Mangili G, Danese S, Scollo P, Lo Russo D, Villa A, Aimone PD, Scambia G. Bolis G, et al. Among authors: raspagliesi f. Eur J Cancer. 2010 Nov;46(16):2905-12. doi: 10.1016/j.ejca.2010.06.124. Epub 2010 Jul 29. Eur J Cancer. 2010. PMID: 20673626 Free article. Clinical Trial.
435 results